^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    abequolixron (RGX-104)

    i
    Other names: RGX-104, RGX104, RGX 104
    Associations

    News

    Trials
    Company:
    Inspirna
    Drug class:
    APOE activator, Liver X receptor agonist
    Associations

    News

    Trials
    11ms
    A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer (clinicaltrials.gov)
    P1, N=146, Completed, Inspirna, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • APOE (Apolipoprotein E)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • docetaxel • pemetrexed • abequolixron (RGX-104)
    11ms
    Abequolixron (RGX-104) and Durvalumab in Lung Cancer (clinicaltrials.gov)
    P1, N=1, Terminated, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Feb 2029 --> Feb 2025 | Active, not recruiting --> Terminated; Sponsor is closing the trial.
    Trial completion date • Trial termination
    |
    carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel • pemetrexed • abequolixron (RGX-104)
    11ms
    Abequolixron (RGX-104) and Durvalumab in Lung Cancer (clinicaltrials.gov)
    P1, N=1, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=24 --> 1 | Trial completion date: Dec 2026 --> Feb 2029 | Trial primary completion date: Dec 2025 --> Sep 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel • pemetrexed • abequolixron (RGX-104)
    over1year
    A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer (clinicaltrials.gov)
    P1, N=146, Active, not recruiting, Inspirna, Inc. | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • APOE (Apolipoprotein E)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • docetaxel • pemetrexed • abequolixron (RGX-104)
    over1year
    Abequolixron (RGX-104) and Durvalumab in Lung Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel • pemetrexed • abequolixron (RGX-104)
    over1year
    A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer (clinicaltrials.gov)
    P1, N=146, Active, not recruiting, Inspirna, Inc. | Recruiting --> Active, not recruiting | Trial completion date: May 2024 --> Sep 2024 | Trial primary completion date: Dec 2023 --> Sep 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • APOE (Apolipoprotein E)
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • docetaxel • pemetrexed • abequolixron (RGX-104)
    almost2years
    Abequolixron (RGX-104) and Durvalumab in Lung Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, UNC Lineberger Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel • pemetrexed • abequolixron (RGX-104)
    almost2years
    Pilot Study of Abequolixron (RGX-104) and Durvalumab in Lung Cancer (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center | Initiation date: Nov 2023 --> Mar 2024
    Trial initiation date • Combination therapy
    |
    carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel • pemetrexed • abequolixron (RGX-104)
    2years
    A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer (clinicaltrials.gov)
    P1, N=150, Recruiting, Inspirna, Inc.
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • APOE (Apolipoprotein E)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • docetaxel • pemetrexed • abequolixron (RGX-104)
    over2years
    Pilot Study of Abequolixron (RGX-104) and Durvalumab in Lung Cancer (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center
    New P1 trial • Combination therapy
    |
    carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel • pemetrexed • abequolixron (RGX-104)
    over3years
    Immunomodulatory-Photodynamic Nano-Stimulators for Invoking Pyroptosis to Augment Tumor Immunotherapy. (PubMed, Adv Healthc Mater)
    Herein, acidic tumor microenvironment (TME)-evoked MRC nanoparticles (MRC NPs) co-delivering immune agonist RGX-104 and photosensitizer chlorine e6 (Ce6) are reported for pyroptosis-mediated immunotherapy...MRC-elicited pyroptosis in combination with anti-PD-1 blockade therapy boosts immune response in solid tumors, successfully arresting invasive metastasis and extending survival based on its remarkable antitumor immunity. MRC may initiate a new window for immuno-photo pyroptosis stimulators augmenting pyroptosis-based immunotherapy.
    Journal
    |
    APOE (Apolipoprotein E) • GSDME (Gasdermin E)
    |
    abequolixron (RGX-104)
    over3years
    A Study of RGX-104 in Patients With Advanced Solid Malignancies (clinicaltrials.gov)
    P1, N=150, Recruiting, Inspirna, Inc. | Trial completion date: Mar 2022 --> May 2024 | Trial primary completion date: Dec 2021 --> Dec 2023
    Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • APOE (Apolipoprotein E)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • docetaxel • pemetrexed • abequolixron (RGX-104)